Shionogi sets up US drug discovery venture
This article was originally published in Scrip
Executive Summary
Shionogi has set up a new US-based joint venture to conduct basic drug discovery and biomarker research. Ezose Sciences is based in New Jersey and is 87%-owned by the Japanese drug company. Sumitomo Bakelite, a diversified Japanese materials company, holds the remainder. The new operation will provide high-throughput services designed to identify disease-related proteins, using glycan and glycoprotein markers to determine the structure of the parent protein.